Trials / Completed
CompletedNCT02068222
A Study to Evaluate the Safety and Antiviral Effect of ABT-450/Ritonavir and ABT-530 Coadministered With and Without Ribavirin in Adults With Genotype 3 Hepatitis C (HCV) Infection
An Open-Label Pilot Study to Evaluate the Antiviral Activity, Safety, Tolerability, and Pharmacokinetics of ABT-450 With Ritonavir (ABT-450/r) Dosed in Combination With ABT-530, With and Without Ribavirin (RBV) in Treatment-Naïve Subjects With Genotype 3 Chronic Hepatitis C Virus (HCV) Infection
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 10 (actual)
- Sponsor
- AbbVie · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and antiviral effect of ABT-450/r and ABT-530 coadministered with and without Ribavirin in adults with genotype 3 HCV infection.
Detailed description
Once the efficacy and safety data were obtained from participants administered ABT-450/r + ABT-530 + RBV weight-based (Arm 1) in Study M14-213, the decision was made to end this study before subjects were enrolled into Arm 2.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ABT-450/ritonavir (r) | Tablet |
| DRUG | ABT-530 | Tablet |
| DRUG | Ribavirin (RBV) | Tablet |
Timeline
- Start date
- 2014-04-01
- Primary completion
- 2015-03-01
- Completion
- 2015-03-01
- First posted
- 2014-02-21
- Last updated
- 2018-02-22
- Results posted
- 2017-02-02
Source: ClinicalTrials.gov record NCT02068222. Inclusion in this directory is not an endorsement.